Literature DB >> 19291785

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

Luca Miele1, Venanzio Valenza, Giuseppe La Torre, Massimo Montalto, Giovanni Cammarota, Riccardo Ricci, Roberta Mascianà, Alessandra Forgione, Maria L Gabrieli, Germano Perotti, Fabio M Vecchio, Gianlodovico Rapaccini, Giovanni Gasbarrini, Chris P Day, Antonio Grieco.   

Abstract

UNLABELLED: The role played by the gut in nonalcoholic fatty liver disease (NAFLD) is still a matter of debate, although animal and human studies suggest that gut-derived endotoxin may be important. We investigated intestinal permeability in patients with NAFLD and evaluated the correlations between this phenomenon and the stage of the disease, the integrity of tight junctions within the small intestine, and prevalence of small intestinal bacterial overgrowth (SIBO). We examined 35 consecutive patients with biopsy-proven NAFLD, 27 with untreated celiac disease (as a model of intestinal hyperpermeability) and 24 healthy volunteers. We assessed the presence of SIBO by glucose breath testing (GBT), intestinal permeability by means of urinary excretion of (51)Cr-ethylene diamine tetraacetate ((51)Cr-EDTA) test, and the integrity of tight junctions within the gut by immunohistochemical analysis of zona occludens-1 (ZO-1) expression in duodenal biopsy specimens. Patients with NAFLD had significantly increased gut permeability (compared with healthy subjects; P < 0.001) and a higher prevalence of SIBO, although both were lower than in the untreated celiac patients. In patients with NAFLD, both gut permeability and the prevalence of SIBO correlated with the severity of steatosis but not with presence of NASH.
CONCLUSIONS: Our results provide the first evidence that NAFLD in humans is associated with increased gut permeability and that this abnormality is related to the increased prevalence of SIBO in these patients. The increased permeability appears to be caused by disruption of intercellular tight junctions in the intestine, and it may play an important role in the pathogenesis of hepatic fat deposition.

Entities:  

Mesh:

Year:  2009        PMID: 19291785     DOI: 10.1002/hep.22848

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  454 in total

1.  Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver.

Authors:  Michal Ganz; Timea Csak; Bharath Nath; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids.

Authors:  Lotta K Stenman; Reetta Holma; Riitta Korpela
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 4.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

5.  Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats.

Authors:  Dan-Hong Yang; Zai-Yuan Ye; Yuan-Jun Xie; Xu-Jun He; Wen-Juan Xu; Wei-Ming Zhou
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

6.  Microbiome-Immune Interactions and Liver Disease.

Authors:  James H Tabibian; Cyril Varghese; Steven P O'Hara; Nicholas F LaRusso
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-05-07

7.  Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Authors:  Magar Ghazarian; Xavier S Revelo; Mark K Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D'Angelo; Peter Horton; William C Chapman; Diane Brockmeier; Minna Woo; Edgar G Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J Gehring; Shawn Winer; Daniel A Winer
Journal:  Sci Immunol       Date:  2017-04-21

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Enea Bonci; Lidia Marandola; Sara Romaggioli; Stefano Bascetta; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Pediatric small intestine bacterial overgrowth in low-income countries.

Authors:  Jeffrey R Donowitz; William A Petri
Journal:  Trends Mol Med       Date:  2014-11-15       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.